Regeneron Pharmaceuticals, Inc.
Market Cap
$73.47B
P/E Ratio
17.25
EPS
$40.98
Dividend Yield
0.48%
52-Week Range
$476.49 — $821.11
Volume
1.03M
Avg Volume
688.92K
Beta
0.40
Get alerted when REGN hits your target price.
Free — enter your email to get started
P/E (TTM)
17.25
Forward P/E
15.59
PEG Ratio
-23.22
P/S (TTM)
5.42
P/B (TTM)
2.47
P/FCF
0.00
EV/EBITDA
74.83x
EV/Sales
—
ROE (TTM)
0.15%
ROA (TTM)
0.11%
ROIC
0.03%
Gross Margin
0.85%
Operating Margin
0.25%
Net Margin
0.22%
Debt/Equity
0.09
Current Ratio
4.13
EPS Growth (YoY)
-0.03%
Revenue Growth (YoY)
+0.07%
EPS Growth (3Y)
+0.02%
EPS Growth (5Y)
+0.19%
Sales Growth (3Y)
+0.06%
Sales Growth (5Y)
+0.16%
EPS Est (This Year)
$45.34
EPS Est (Next Year)
$52.73
Dividend Yield
—
Annual Dividend
$0.88
Payout Ratio
0.11%
Frequency
—
Ex-Dividend Date
2025-11-20
Cash/Share
$83.63
Strong Buy
1 = Strong Buy, 5 = Strong Sell
Price Target Range
Consensus Target: $857.17(21.2% upside)
Institutional %
15.45%
Inst. Net Change
444.68K
Insider Net Shares (90d)
-3974
Outstanding Shares
103.90M
Float
98.54M
Free Float %
94.84%
RSI (14)
56.49
SMA 20
$756.63
SMA 50
$757.98
SMA 200
$633.09
ATR (14)
22.74
Volatility (Week)
0.02%
Volatility (Month)
0.02%
Pattern
—
1 Day
-3.25%
1 Week
-0.56%
1 Month
-5.23%
3 Months
+14.81%
6 Months
+38.28%
1 Year
—
YTD
-2.76%
All-Time High
$821.11
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
NASDAQ
IPO Date
1991-04-02
Employees
15158
CEO
Leonard S. Schleifer
Index Membership
S&P 500
Website
https://www.regeneron.com
Regeneron Pharmaceuticals, Inc. (REGN) is a healthcare company in the biotechnology industry listed on the NASDAQ. With a market capitalization of $73.47B, a P/E ratio of 17.25, and a dividend yield of 0.48%, REGN is tracked by stockscreenr alongside 25,000+ other tickers. Use the free stock screener to compare REGN against other stocks using dozens of fundamental and technical filters.
Regeneron Pharmaceuticals, Inc. (REGN) has a trailing twelve-month (TTM) P/E ratio of 17.25. This is near the market average range. The P/E ratio measures how much investors are willing to pay per dollar of earnings.
No, Regeneron Pharmaceuticals, Inc. (REGN) does not currently pay a regular dividend. The company may be reinvesting profits into growth, research, or debt reduction instead of returning cash to shareholders through dividends.
Regeneron Pharmaceuticals, Inc. (REGN) has a market capitalization of $73.47 billion, classifying it as a large-cap company. Market cap is calculated by multiplying the current share price by the total number of outstanding shares.
Wall Street analysts have a consensus "Strong Buy" rating on Regeneron Pharmaceuticals, Inc. (REGN) with an average score of 1.50 on a 1-5 scale (1 = Strong Buy, 5 = Strong Sell). The consensus price target of $857.17 implies 21.2% upside from the current price.
Regeneron Pharmaceuticals, Inc. (REGN) has returned -2.76% year-to-date. Past performance does not guarantee future results, but these figures reflect the stock's recent price trajectory relative to the broader market.